Heart Failure - At Home-HF Pilot

A Multicenter, Randomized, Open Label, Controlled Study Evaluating the Effectiveness and Safety of Furoscix On-Body Infusio versus Continued Medical Therapy for Worsening Heart Failure

Dr. Radojevic and the Heart Failure Team are participating in this trial to evaluate the efficacy and safety of the Furoscix  Infusor versus continued medical therapy in patients with chronic heart failure and fluid overload.

Eligibility Criteria:

  • Symptomatic Chronic Heart Failure
  • Daily Furosemide dose (40-160 mg)

Please contact Khadija El Aoudi at 860-972-3167 or by email Khadija.elaoudi@hhchealth.org for more information